Please login to the form below

Not currently logged in
Email:
Password:

Nexavar

This page shows the latest Nexavar news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s plans for Inlyta go awry with failed adjuvant trial

Pfizer’s plans for Inlyta go awry with failed adjuvant trial

line setting after a trial pitting it against Bayer’s first-line VEGF drug Nexavar (sorafenib) failed to show any improvement in progression-free survival.

Latest news

  • NICE backs EUSA's RCC treatment Fotivda NICE backs EUSA's RCC treatment Fotivda

    It showed patients treated with EUSA’s drug experienced a superior progression-free survival of 11.9 months verses Nexavar (9.1 months) and an improved side effect profile, with only ... 14% of patients on Fotivda requiring a dose reduction due to

  • Keytruda adds stomach cancer to growing list of US approvals Keytruda adds stomach cancer to growing list of US approvals

    Opdivo has also just picked up a US approval as a second-line treatment for hepatocellular carcinoma - a common form of liver cancer - in patients previously treated with Bayer’s Nexavar

  • EUSA receives European green light for kidney cancer treatment Fotivda EUSA receives European green light for kidney cancer treatment Fotivda

    trial. This evaluated the efficacy and tolerability of the drug compared to Bayer’s currently available VEGFR-TKI treatment Nexavar (sorafenib).

  • Bayer's Nexavar backed by NICE for liver cancer Bayer's Nexavar backed by NICE for liver cancer

    Bayer's Nexavar backed by NICE for liver cancer. The drug is the only approved first-line treatment for advanced HCC. ... Bayer's Nexavar will be available for routine use for liver cancer by NHS England clinics - and not just via the Cancer Drugs Fund -

  • EMA clears Bayer's Stivarga for liver cancer EMA clears Bayer's Stivarga for liver cancer

    The European Medicines Agency (EMA) approved oral multikinase inhibitor Stivarga (regorafenib) for patients with HCC who have been treated first-line with Bayer's older drug Nexavar (sorafenib), matching the ... Nexavar is the only approved first-line

More from news
Approximately 9 fully matching, plus 96 partially matching documents found.

Latest Intelligence

  • Deal Watch table for August 2013 Deal Watch table for August 2013

    Onyx Pharmaceuticals / Amgen. Acquisition. Cancer drugs including Kyprolis, Nexavar and Stivarga.

  • Pharma deals during August 2013 Pharma deals during August 2013

    To add to the glitter are two marketed drugs partnered with Bayer: Nexavar (sorafenib) for the treatment of advanced kidney and liver cancer and Stivarga (regorafenib) for the treatment of metastatic

  • Intellectual property threats in the BRIC markets Intellectual property threats in the BRIC markets

    The recent upholding of the Indian patent office's rejection of Novartis' Glivec patent application is the latest in a series of actions including the compulsory licence of Nexavar and initiation

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Oncology drugs under AMNOG

    In its phase 3 trial it was compared with a single rival targeted therapy, Nexavar (sorafenib). ... A benefit was found for Inlyta compared with Nexavar in the cytokine treatment group, on the basis of increased tolerability.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Anthill is a specialist digital agency and a strategic partner for life science companies....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics